Breakthrough | Organ like chip replaces animal experiments for the first time, approved drug IND, accelerating the development of thousands of new drugs for diseases

Breakthrough | Organ-like chip replaces the approved drug IND in animal experiments for the first time, and accelerates the development of new drugs for thousands of diseases

2022-08-08

3565

1659930255609038. png

Organoids on Chips technology has also made rapid progress. Recently, the application of organoid chips in preclinical research has reached a new milestone:The research of this kind of organ chip was carried out jointly by Hesperos and Sanofi. Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) are two rare autoimmune demyelinating neuropathy. Scientists of Hesperos use motor neurons differentiated from human induced pluripotent stem cells (iPSC) and human Schwann cell We constructed organoid chip models for these two diseases

1659930398394834. png

Among these diseases, Autoantibodies can damage nerve cells and slow down the transmission of information from the brain to muscles, leading to symptoms of muscle weakness< Span style="font size: 18px; color: rgb (54, 96, 146);">Researchers used organoid chip models to reproduce the attack of autoantibodies on the myelin sheath, resulting in a decrease in the transmission speed of neural electrical signals. On this in vitro biomimetic organoid chip pathological model, the antibody TNT-005 targeting the complement system developed by Sanofi was administered, and the results showed that TNT005 can restore its neural function

These data lay the foundation for Sanofi's use of the approved therapy sutimlimab targeting complement C1s protein to treat these two types of demyelinating diseases.. Sutimlimab has been approved by the FDA for use in the treatment of patients with cold agglutinin disease. Sanofi will compare the safety data obtained from sutimlimab in the treatment of patients with cold agglutinin disease with the use of